2019:全球乙肝药物研发管线(HBV Pipeline)

2019-05-15 不详 网络

正大天晴(TLR7激动剂-强生)、恒瑞医药(TLR-7)、齐鲁制药、东阳光药、挚盟医药、歌礼药业、亚盛医药、贺普生物等等。

中国药企在做乙肝药物的有:

正大天晴(TLR7激动剂-强生)、恒瑞医药(TLR-7)、齐鲁制药、东阳光药、挚盟医药、歌礼药业、亚盛医药、贺普生物等等。

下边来自HBV基金会,仅供参考:

FAMILY/DRUG NAME(药物名称)

MECHANISM

(药物机制)

COMPANY

(公司)

WEBSITE

(网站)

USA STATUS

Interferons: Mimic infection-fighting immune substances naturally produced in the body.

Intron A (Interferon alfa-2b)

Immunomodulator

Merck, USA

merck.com

Approved 1991

Pegasys (Peginterferon alfa-2a)

Immunomodulator

Genentech, USA

gene.com

Approved 2005


Nucleos(t)ide Analogues: Interfere with viral DNA polymerase used for HBV replication

Epivir (Lamivudine)
*Generics available

Inhibits viral DNA polymerase

GlaxoSmithKline (GSK)

gsk.com

Approved 1998

Hepsera (Adefovir dipivoxil)
*Generics available

Inhibits viral DNA polymerase

Gilead Sciences, USA

gilead.com

Approved 2002

Baraclude (Entecavir)
*Generics available

Inhibits viral DNA polymerase

Bristol-Myers Squibb, USA

bms.com

Approved 2005

Tyzeka (Telbivudine)
*Generic available

Inhibits viral DNA polymerase

Novartis, USA

novartis.com

Approved 2006


Viread (Tenofovir)
*Generics available

Inhibits viral DNA polymerase

Gilead Sciences

gilead.com

Approved 2008

Vemlidy (TAF or tenofovir alafenamide)

Prodrug of tenofovir

Gilead Sciences

gilead.com

Approved 2016

Levovir (Clevudine)

Inhibits viral DNA polymerase

Bukwang, S. Korea

bukwang.co.kr

Approved 2006 in S. Korea

Besivo (formerly ANA 380/LB80380)

Inhibits viral DNA polymerase

Ildong Pharma, S. Korea

ildong.com/en

Approved 2017 in S. Korea

Zadaxin

Immunomodulator

SciClone, USA

sciclone.com

Approved outside USA

DIRECT ACTING ANTIVIRALS: Targets the virus and interferes in the HBV replication process

TDF Pro Drugs: A modified tenofovir drug that can get into liver cells more easily

TXL (CMX 157)

Prodrug of tenofovir

ContraVir, USA

contravir.com

Phase II

Silencing RNA’s (siRNAs): Interferes and destroys viral RNA

ARB-1467

RNAi gene silencer (1.0)

Arbutus Biopharma, USA

arbutusbio.com

Phase II

RG6004

RNAi gene silencer

Roche, Switzerland

roche.com

Phase I/II

ARO-HBV

RNAi gene silencer

Arrowhead Pharma, USA

arrowheadpharma.com

Phase I/II

AB-729

RNAi gene silencer

Arbutus Biopharma, USA

arbutusbio.com

Phase I

Vir-2218

RNAi gene silencer

Alnylam and Vir Biotech, USA

alnylam.com

Phase I/II

DCR-HBVS

RNAi gene silencer

Dicerna, USA

dicerna.com

Phase I

BB-103

RNAi gene silencer

Benitec, Australia

benitec.com

Preclinical

Lunar-HBV

RNAi gene silencer

Arcturus, USA with Janssen

arcturusrx.com

Preclinical

Entry Inhibitors: Interferes with HBV getting into liver cells

Myrcludex B
(bulevirtide)

Entry inhibitor

Hepatera, Russia with MYR GmbH, Germany

myr-pharma.com

Phase IIb

Capsid Inhibitors: Interferes with the viral DNA protein shield

Morphothiadin (GLS4)

Capsid inhibitor

HEC Pharma,
PR China(东阳光)

pharm.hec.cn/en

Phase II

JNJ 56136379

Capsid inhibitor

Janssen, Scotland

janssen.com

Phase II

ABI-H0731

Capsid inhibitor

Assembly Biosciences, USA

assemblybio.com

Phase II

AB-423

Capsid inhibitor

Arbutus Biopharma, USA

arbutusbio.com

Phase I

AB-506

Capsid inhibitor

Arbutus Biopharma, USA

arbutusbio.com/

Phase I

ABI-H2158

Capsid inhibitor

Assembly Biosciences, USA

assemblybio.com

Phase I

RG7907

Capsid inhibitor

Roche, Switzerland

roche.com

Phase I

QL-007

Capsid inhibitor

Qilu, China(齐鲁)

qilu-pharma.com

Phase I

GLP-26

Capsid inhibitor

Emory University

emory.edu

Preclinical

EP-027367

Capsid inhibitor

Enanta Pharmaceuticals, USA

enanta.com

Preclinical

QL-0A6a

Capsid inhibitor

Qilu, China

qilu-pharma.com

Preclinical

CB-HBV-001

Capsid inhibitor

ZhiMeng Biopharma, China(挚盟医药)

core-biopharma.com

Preclinical

HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg)

REP 2139

sAg inhibitor

Replicor, Canada

replicor.com

Phase II

REP 2165

sAg inhibitor

Replicor, Canada

replicor.com

Phase II

Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein

IONIS-HBVRx (GSK3228836)

Viral protein inhibitor

Ionis Pharma, USA with GSK

ionispharma.com

Phase II

IONIS-HBVLRx (GSK33389404)

Viral protein inhibitor

Ionis Pharma with GSK

ionispharma.com

Phase II


Ribonuclease H Inhibitors: Inhibit degradation of viral RNA

ARB-452

Viral RNase Inhibitor

Arbutus Biopharma, USA

arbutusbio.com

Preclinical

INDIRECT ACTING ANTIVIRALS: Targets the human immune system to attack the HBV virus

Therapeutic Vaccines: Vaccine technology used to stimulate the immune system as a treatment

ABX203

Therapeutic vaccine

Center for Genetic Engineering and Biotechnology, Cuba

cigb.edu.cu/en

Phase III

AIC 649

Therapeutic vaccine

AiCuris, Germany

aicuris.com

Phase I

INO-1800

Therapeutic vaccine

Inovio, USA

inovio.com

Phase I

HB-110

Therapeutic vaccine

Ichor Medical Systems with Janssen, USA

ichorms.com

Phase I

TG1050

Therapeutic vaccine

Transgene, France

transgene.com

Phase I

HepTcell

Therapeutic vaccine

Altimmune, USA

altimmune.com

Phase I

HBV (TomegaVax)

Therapeutic vaccine

TomegaVax, USA

tomegavax.com

Preclinical

HBV

Therapeutic vaccine

GeoVax Labs, USA

geovax.com

Preclinical

VR-CHB01

Therapeutic vaccine

Vical, USA

vical.com

Preclinical

VBI-2601

Therapeutic vaccine

VBI Vaccines, USA with Brii Biosciences

vbivaccines.com

Preclinical

Chimigen HBV

Therapeutic vaccine

Akshaya Bio Inc., Canada

akshayabio.com

Preclinical

CARG-201

Therapeutic vaccine

CaroGen Crop

carogencorp.com

Preclinical

Innate Immune Defense Pathway: Compounds that activate the innate immune system

RG7795

TLR-7 agonist

Roche, Switzerland

roche.com

Phase II

Inarigivir (SB9200)

RIG -1 and NOD2 agonist

Spring Bank Pharmaceuticals, USA
Gilead Sciences

springbankpharm.com
gilead.com

Phase II

GS9688

TLR-8 agonist

Gilead Sciences, USA

gilead.com

Phase I

RG7854

TLR-7 agonist

Roche, Switzerland

roche.com

Phase I

Host Acting Pathway: Compounds that induce programmed cell death (apoptosis)

APG-1387

Apoptosis Inducer

Ascentage Pharma, China(亚盛)

en.ascentagepharma.com

Phase I

CRV 431 (CPI 431-32)

Ciclofillin inhibitor

ContraVir, USA

contravir.com

Preclinical

Gene Editing

EBT106

CRISPR/Cas 9

Excision Biotherapeutics, USA

www.excisionbio.com

Preclinical

HBV

CRISPR/Cas 9

Intellia Therapeutics, USA

intelliatx.com

Preclinical

HBV

ARCUS

Precision Biopharma, USA with Gilead

precisionsciences.com

Preclinical


Other

GC1102

sAg monoclonal antibody

Green Cross, South Korea

www.globalgreencross.com

Phase II

EYP001

FXR agonist

Enyo Pharma, France

enyopharma.com

Phase I

LTCR-H2-1

T Cell immunotherapy

Lion TCR, Singapore

www.liontcr.com

Preclinical

IMMTav

T Cell immunomodulator

Immunocore, USA

immunocore.com

Preclinical

HBV

MicroRNA

Regulus Therapeutics, USA

regulusrx.com

Preclinical

HEPATITIS DELTA VIRUS (HDV)

Lambda (Pegylated Interferon)

Immunomodulator

Eiger Biopharma, USA

eigerbio.com

Orphan drug designation
Phase III

Myrcludex B
(bulevirtide)

Entry inhibitor

MYR-GmbH, Germany

myr-pharma.com

Breakthrough Therapy Designation
Phase III

Lonafarnib

Prenylation inhibitor

Eiger Biopharma, USA

eigerbio.com

FDA Fast Track Designation
Orphan drug designation
Phase II

REP 2139/ REP 2165

HBsAg inhibitor

Replicor, Canada

replicor.com

Phase II

Ezetimibe

NTCP inhibitor

Ziauddin University Hospital, Pakistan

zu.edu.pk

Phase II

ALN-HDV

RNAi gene silencer

Alnylam, USA

alnylam.com

Preclinical

GI-18000

Immune Response Stimulator

GlobeImmune

globeimmune.com

Preclinical


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1836684, encodeId=275c18366841a, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 17 09:54:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727988, encodeId=d6a21e2798893, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Feb 16 13:54:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300264, encodeId=d0f4130026473, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301465, encodeId=dee01301465fa, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625835, encodeId=18171625835b0, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-08-17 klivis
  2. [GetPortalCommentsPageByObjectIdResponse(id=1836684, encodeId=275c18366841a, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 17 09:54:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727988, encodeId=d6a21e2798893, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Feb 16 13:54:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300264, encodeId=d0f4130026473, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301465, encodeId=dee01301465fa, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625835, encodeId=18171625835b0, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2020-02-16 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1836684, encodeId=275c18366841a, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 17 09:54:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727988, encodeId=d6a21e2798893, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Feb 16 13:54:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300264, encodeId=d0f4130026473, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301465, encodeId=dee01301465fa, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625835, encodeId=18171625835b0, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-05-17 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=1836684, encodeId=275c18366841a, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 17 09:54:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727988, encodeId=d6a21e2798893, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Feb 16 13:54:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300264, encodeId=d0f4130026473, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301465, encodeId=dee01301465fa, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625835, encodeId=18171625835b0, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1836684, encodeId=275c18366841a, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Aug 17 09:54:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727988, encodeId=d6a21e2798893, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Feb 16 13:54:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300264, encodeId=d0f4130026473, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301465, encodeId=dee01301465fa, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625835, encodeId=18171625835b0, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Fri May 17 06:54:00 CST 2019, time=2019-05-17, status=1, ipAttribution=)]
    2019-05-17 tidiq

相关资讯

乙肝患者患肝癌几率有多高?

我们知道,乙肝有很大的几率会癌变,通常是先演变成肝硬化,接着就是肝癌。很多人都会有一个误解,以为乙肝就一定会变成肝癌,其实这也不正确!确实,许多肝癌患者是因为刚开始感染乙肝病毒长期得不到治疗,从而出现慢性乙肝的症状。如果进一步恶化,容易出现肝硬化的症状,最后形成肝癌。 但是,不是所有的乙肝都会变成肝癌,患有乙肝而终身不癌变的大有人在,有很多人都能活到八九十岁。因此,需要科学对待乙肝,要评估乙 如

Myr Pharma的bulevirtide阻断NTCP,在HBV/HDV合并感染患者中展现出强大的抗病毒作用

德国生物技术公司Myr Pharma报告了在慢性乙型(HBV)和丁型(HDV)肝炎感染患者中使用bulevirtide治疗的2b期临床试验数据,结果显示在某些患者中病毒降至检测不到的水平。

PNAS:对乙肝病毒携带者血液活检可发现早期肝癌

近日,我国科学家研发出通过检测血液中的细胞游离DNA突变和蛋白标志物进行肝癌早期筛查的技术方法,可以从无症状的乙肝病毒携带者中发现早期肝癌。这项技术经过严格的临床验证后,有望建立更加便捷、无创、标准化的肝癌早期筛查方案。该研究成果于北京时间12日由国际权威学术期刊《美国科学院院刊》在线发表。

Int J Epidemiol:艾滋病乙肝梅毒三病联合母婴阻断策略找到

2017年10月,世界卫生组织(WHO)西太区委员会通过了2018-2030年亚洲及太平洋地区艾滋病、乙肝和梅毒三病联合母婴阻断的干预框架,提出了整合干预方案以持续有效地降低并最终消除这三种传染病的母婴传播。为回应WHO的建议,公共卫生学院张磊教授利用柬埔寨孕产妇人群数据,构建了数学预测模型,评估了该整合干预方案的疾病控制效果和成本效果。近日,该研究成果“Integrated approach f

厦门大学夏宁邵团队发表新型乙肝治疗性疫苗的研究成果

3月29日,国际权威胃肠肝病期刊Gut(JCR1区、IF 17.0)在线刊出了厦门大学夏宁邵教授团队发表的题为“A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice”的研究论文。该研究发展了一种新型的B细胞表位嵌合型类病

转氨酶升高,到底是乙肝还是脂肪肝导致的?

张先生,男,45岁,自幼经母亲垂直感染患乙肝,为“小三阳”,HBV DNA也一直阳性,既往每年单位体检,肝功能正常,自以为携带者。